drugset / Trial / NCT00333216
Anecortave Acetate Risk-Reduction Trial (AART)
RandomizedParallel-groupDouble-blindPrevention
Summary
The purpose of this study was to demonstrate that Anecortave Acetate for Depot Suspension (15 mg or 30 mg) is safe and effective in arresting the progression of non-exudative (dry) age-related macular degeneration in patients who are at risk for progressing to exudative (wet) age-related macular degeneration.
Timeline
- Start
- 2005-05
- Primary completion
- 2008-12
- Completion
- 2008-12
Outcome
Outcome not reported
Stopped: “Lack of efficacy”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Anecortave Acetate | Unknown | 15 mg | Other |
| Subject | Anecortave Acetate | Unknown | 30 mg | Other |
Indications
No indication recorded.